A detailed history of China Universal Asset Management Co., Ltd. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 69,527 shares of LXRX stock, worth $49,364. This represents 0.01% of its overall portfolio holdings.

Number of Shares
69,527
Previous 42,469 63.71%
Holding current value
$49,364
Previous $71,000 53.52%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1.51 - $2.39 $40,857 - $64,668
27,058 Added 63.71%
69,527 $109,000
Q2 2024

Jul 19, 2024

SELL
$1.54 - $2.28 $6,869 - $10,171
-4,461 Reduced 9.51%
42,469 $71,000
Q1 2024

Apr 29, 2024

BUY
$1.3 - $3.58 $24,181 - $66,591
18,601 Added 65.66%
46,930 $113,000
Q4 2023

May 21, 2024

SELL
$1.0 - $1.53 $18,601 - $28,459
-18,601 Reduced 39.64%
28,329 $43,000
Q4 2023

Jan 23, 2024

BUY
$1.0 - $1.53 $22,043 - $33,725
22,043 Added 350.67%
28,329 $43,000
Q3 2023

May 21, 2024

BUY
$1.06 - $2.33 $4,029 - $8,856
3,801 Added 152.96%
6,286 $6,000
Q3 2023

Oct 30, 2023

BUY
$1.06 - $2.33 $4,029 - $8,856
3,801 Added 152.96%
6,286 $7,000
Q2 2023

May 21, 2024

SELL
$2.15 - $3.49 $154 - $251
-72 Reduced 2.82%
2,485 $5,000
Q2 2023

Jul 27, 2023

SELL
$2.15 - $3.49 $154 - $251
-72 Reduced 2.82%
2,485 $6,000
Q1 2023

May 21, 2024

BUY
$1.99 - $2.68 $1,271 - $1,712
639 Added 33.32%
2,557 $6,000
Q1 2023

Apr 27, 2023

BUY
$1.99 - $2.68 $1,271 - $1,712
639 Added 33.32%
2,557 $6,000
Q4 2022

May 21, 2024

SELL
$1.8 - $2.56 $81,021 - $115,230
-45,012 Reduced 95.91%
1,918 $3,000
Q4 2022

Jan 31, 2023

BUY
$1.8 - $2.56 $358 - $509
199 Added 11.58%
1,918 $4,000
Q3 2022

Oct 21, 2022

BUY
$1.94 - $3.43 $3,334 - $5,896
1,719 New
1,719 $4,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.